知搜-全球专利检索

  1. 登录
  2. 注册
发明授权
CN108245680B RIPK4作为靶位点在制备治疗膀胱癌药物中的应用 有权

RIPK4作为靶位点在制备治疗膀胱癌药物中的应用
摘要：
本发明的研究表明，BUC中RIPK4明显上调，RIPK4的表达诱导过度，而沉默RIPK4抑制体外和体内BUC的侵袭和转移。因此，RIPK4可作为靶位点在制备治疗膀胱癌药物中的应用。所述膀胱癌是指BUC。此外，我们证明RIPK4的上调会导致血管内皮生长因子A(VEGF‑A)水平增加。因此，RIPK4在制备靶向负性调控VEGF‑A表达制剂中可应用。同时，VEGF‑A也可作为靶位点在制备治疗膀胱癌药物中应用。
摘要（英）：

The invention discloses application of RIPK4 as a target site in preparing urinary bladder carcinoma treating medicine. Researches show that RIPK4 in BUC is obviously improved, expression induction ofthe RIPK4 is excessive, and silent RIPK4 can inhibit in-vitro and in-vivo BUC invasion and metastasis. Therefore, the RIPK4 can serve as the target site to be applied to preparing urinary bladder carcinoma treating medicine. In addition, the condition RIPK4 up-regulation can cause vascular endothelial growth factor A (VEGF-A) level increasing is proved, so that the RIPK4 can be applied to preparing target negative regulation VEGF-A expression preparation. Meanwhile, VEGF-A can serve as a target site to be applied to preparing the urinary bladder carcinoma treating medicine.

公开/授权文献
0/0